LAUSR

Nanomedicine is a promising strategy for improving clinical outcomes for cancer therapies, by improving drug efficacy through enhanced delivery to disease sites. It is of importance for ultimate clinical success to consider the contributing factors to achieving this goal, such as size, chemistry and functionality of nanoparticle delivery systems, and how these parameters influence tumor localization and uptake. This short review will first discuss the evolution and progress of polymeric nanoparti-cles for cancer drug delivery and the current challenges that remain to be addressed. Strategies for overcoming the limita-tions of passive targeting through active targeting approaches, and the current state of such nanomedicines in the clinic will be highlighted. Finally, novel approaches towards the design of active targeted nanoparticles building on our growing under-standing of nano-bio interactions are considered, in order to shed light on future design considerations for accelerating clini-cal translation of nanomedicines.